Skip to main content
MOA Life Plus Co. Ltd. logo

MOA Life Plus Co. Ltd. — Investor Relations & Filings

Ticker · 142760 ISIN · KR7142760008 KO Manufacturing
Open in API
Filings indexed 361 across all filing types
Latest filing 2026-05-18 Proxy Solicitation & In…
Country KR South Korea
Listing KO 142760

About MOA Life Plus Co. Ltd.

http://moalifeplus.com/

MOA Life Plus Co. Ltd. is a biopharmaceutical company that researches and develops innovative medicines and consumer healthcare products. The company's pharmaceutical division focuses on a pipeline of biopharmaceuticals, including immunotherapies, cancer treatments, and vaccines for infectious diseases. A core platform technology utilizes Gamma-Polyglutamic Acid (γ-PGA), a natural amino acid polymer derived from fermented foods, to enhance immune responses and serve as a vaccine adjuvant. The consumer business division provides tailored healthcare solutions for immunity enhancement, skin rejuvenation, and pet care. It also manufactures and supplies γ-PGA-based raw materials for the cosmetics industry.

Recent filings

Filing Released Lang Actions
주주총회소집결의 (임시주주총회)
Proxy Solicitation & Information Statement Classification · 80% confidence The document is a convening notice for an extraordinary shareholders’ meeting, listing date, time, location, record date, board resolution date, attendance, and agenda items. It is a notification sent to shareholders to inform them of and solicit votes for a meeting, matching the description of Proxy Solicitation & Information Statement (PSI), rather than a financial report or other announcement type.
2026-05-18 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 75% confidence The document is a short regulatory announcement setting the shareholder register closure period and record date (기준일 설정), with no substantive financial statements or detailed report attached. It does not announce dividends, financial results, board changes, or capital issuance, nor does it provide any management discussion. It is a standard regulatory notice to shareholders. Therefore, it falls under the generic Regulatory Filings category (RNS).
2026-05-18 Korean
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 98% confidence The document is clearly a Korean “분기보고서” (quarterly report) for the 27th fiscal year 1Q (2026.01.01–2026.03.31), issued in the Korean regulatory 6.5 format. It contains detailed company overview, business description, financial tables, and substantive data for the quarter, matching the definition of an Interim/Quarterly Report. Therefore, it should be classified under IR. Q1 2026
2026-05-15 Korean
[기재정정]주요사항보고서(주권관련사채권양도결정)
Regulatory Filings Classification · 85% confidence The document is a Korean ‘주요사항보고서’ correction filing (정정신고) regarding the transfer of bond securities, submitted to the Financial Supervisory Service/Korea Exchange. It details amendments to transaction dates and payment terms for a bond transfer. It is not an earnings report, management discussion, capital raise announcement in the sense of new issuance, or a formal financial report; rather it is a regulatory disclosure of a material transaction. This falls under general regulatory announcements (fallback), so it should be classified as Regulatory Filings (RNS).
2026-05-15 Korean
[기재정정]주요사항보고서(전환사채권발행결정)
Capital/Financing Update Classification · 78% confidence The document is a Korean "주요사항보고서" (Material Event Report) specifically detailing (and correcting) the terms of a convertible bond issuance decision by the company. It is not an annual or interim report, earnings release, governance statement, or call transcript. Instead, it constitutes a financing event disclosure about raising capital via convertible bonds, which falls under updates on company fundraising and capital structure changes. Therefore the correct filing category is Capital/Financing Update (CAP).
2026-05-13 Korean
주요사항보고서(전환사채권발행결정)
Capital/Financing Update Classification · 85% confidence The document is a Korean ‘주요사항보고서’ disclosing the board resolution to issue 5,000,000,000 KRW of private convertible bonds, detailing all terms and conditions (interest, maturity, conversion price and ratio, adjustment clauses, put/call options, use of proceeds, etc.). This is not the bond instrument itself but an official financing announcement. It clearly falls under the company’s financing/capital structure changes rather than, for example, a simple share issue notice. Hence it is best classified as a Capital/Financing Update.
2026-04-16 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.